RPRX - Royalty Pharma plc

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
2,237,215
2,237,215
2,289,463
2,122,000
1,814,254
Operating expenses
Research development
177,106
177,106
200,084
26,000
83,036
Selling general and administrative
227,303
227,303
182,826
182,000
103,439
Total operating expenses
1,314,323
1,314,323
858,748
527,000
-808,922
Operating income or loss
922,892
922,892
1,430,715
1,595,000
2,623,176
Interest expense
187,961
187,961
166,142
157,000
268,573
Total other income/expenses net
-583,202
-583,202
-76,907
263,000
84,487
Income before tax
230,064
230,064
1,241,201
1,702,000
2,461,419
Income tax expense
0
0
0
0
0
Income from continuing operations
230,064
230,064
1,241,201
1,702,000
2,461,419
Net income
42,832
42,832
619,728
975,000
2,348,535
Net income available to common shareholders
42,832
42,832
619,728
975,000
1,187,270
Basic EPS
-
0.10
1.49
1.32
6.63
Diluted EPS
-
0.10
1.49
1.32
6.63
Basic average shares
-
437,963
414,794
375,444
354,176
Diluted average shares
-
437,972
414,802
375,455
354,176
EBITDA
-
423,695
1,430,339
1,882,000
2,753,916